|
gptkbp:instanceOf
|
gptkb:drug
gptkb:antiarrhythmic_agent
|
|
gptkbp:administeredBy
|
gptkb:tablet
extended-release tablet
|
|
gptkbp:approvedBy
|
1980s
|
|
gptkbp:ATCCode
|
C01BC03
|
|
gptkbp:brand
|
Rythmol
Rytmonorm
|
|
gptkbp:CASNumber
|
54063-53-5
|
|
gptkbp:contraindication
|
cardiogenic shock
electrolyte imbalance
severe heart failure
severe hypotension
marked bradycardia
|
|
gptkbp:discoveredBy
|
gptkb:Knoll_AG
|
|
gptkbp:drugClass
|
Class 1c antiarrhythmic
|
|
gptkbp:eliminationHalfLife
|
2-10 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C21H27NO3
|
|
gptkbp:KEGGID
|
D08411
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
sodium channel blocker
beta-adrenergic blocking activity
|
|
gptkbp:MeSH_ID
|
D011345
|
|
gptkbp:metabolism
|
gptkb:CYP1A2
gptkb:CYP2D6
gptkb:CYP3A4
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
90-95%
|
|
gptkbp:PubChem_CID
|
CHEMBL1377
4945
DB01182
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
dizziness
hypotension
bradycardia
metallic taste
worsening of arrhythmia
|
|
gptkbp:synonym
|
propafenona
propafenonum
|
|
gptkbp:UNII
|
Z9PA0B1YXN
|
|
gptkbp:usedFor
|
gptkb:atrial_fibrillation
ventricular arrhythmias
treatment of cardiac arrhythmias
paroxysmal supraventricular tachycardia
|
|
gptkbp:bfsParent
|
gptkb:Class_I_antiarrhythmic_drugs
gptkb:Organic_cation_transporter_1
gptkb:Rhythmol
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
propafenone
|